A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using ...

The FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

Health insurers, providers, and consumer advocates praised the Trump administration’s long-awaited fixes to the No Surprises ...

At the world's largest cancer research meeting, new data were plentiful. But this year, there was also a focus on grief.

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Tara covers the business of health ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.